Precision Biomarkers and Spatial Intelligence for Driving ADC Therapies

From discovery to development—actionable insights that move your ADCs forward

InSituPlex® assays accelerate ADC therapeutic development by providing high-fidelity, quantitative biomarker detection (>90% concordance with current pathology gold standard) and exceptional precision

DAB Assay 0 1+

InSituPlex® Assay 0 1+ 1+ 2+ 3+

HER2 Detection with InSituPlex® assay is concordant with the current Pathology Gold Standard, DAB



Broad Dynamic Range of Detection

Accurate quantitative detection of variable biomarker expression through direct detection and visualization of targets (e.g. HER2 – 0+, 1+, 2+, 3+)



Pathology-Grade Precision

Robust multiplexed biomarker co-detection, with coefficients of variation significantly less than 20% across independent runs



Accelerated Timelines

Fast and agile custom panel development within 6-8 weeks, compared to 6+ months, owing to simplicity and modularity of InSituPlex® assays





State-of-the-Art Spatial Analysis

Advanced spatial insights via STARVUE™ Al-enhanced spatial image data science (e.g. TROP2 expression – membrane vs. cytoplasm)



Customizable OmniVUE™ panels built from a validated menu of 30+ biomarkers, including TROP2, HER2, TF, and FR





Orders of magnitude greater signal amplification; signal-to-noise ratio of up to 30:1

Build, deploy and iterate panels 3x faster, saving months – year(s) of time

Deeper insights from state-of-the-art, Al-enabled spatial image analysis

OmniVUE[™] panels enable researchers to visualize and quantify the complex spatial relationships between tumor cells, immune cells, and therapeutic targets, providing critical insights for ADC development



Interested in additional information and a discussion on how we can help? Reach out to us:





